Skip to main content

ORTHOFIX International N V Value Stock - Dividend - Research Selection

Orthofix international n v

ISIN: US68752M1080 , WKN: A2NB0X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Orthofix International N.V., a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures. The Extremity Fixation segment designs, develops, and markets orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. The Spine Fixation segment designs, develops, and markets a portfolio of implant products used in surgical procedures of the spine. The Biologics segment provides a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. Orthofix International N.V. was founded in 1987 and is headquartered in Lewisville, Texas.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Orthofix Names Andres Cedron as New Chief Legal Officer

2024-04-16
LEWISVILLE, Texas, April 16, 2024--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that Andres Cedron has joined the company as Chief Legal Officer.

Orthofix names Andres Cedron chief legal officer

2024-04-16
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Orthofix Announces Upcoming Board Member Changes

2024-04-12
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Lucas Vitale Joins Orthofix as Chief People and Business Operations Officer

2024-03-18
LEWISVILLE, Texas, March 18, 2024--Former NuVasive executive joins Orthofix as Chief People and Business Operations Officer.

Orthofix names Lucas Vitale chief people, business operations officer

2024-03-18
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Orthofix (OFIX) Q4 Earnings Beat Estimates, Gross Margin Up

2024-03-12
Orthofix's (OFIX) fourth-quarter earnings and revenues beat their respective consensus estimate. Gross margin expands while the company continues to incur losses at the operating level.

Orthofix Medical Inc (OFIX) Reports Significant Sales Growth and Improved EBITDA in Q4 and Full ...

2024-03-07
Orthofix Medical Inc (OFIX) released its 8-K filing on March 5, 2024, showcasing a year of substantial growth and operational efficiency

Orthofix Medical Inc. (NASDAQ:OFIX) Q4 2023 Earnings Call Transcript

2024-03-07
Orthofix Medical Inc. (NASDAQ:OFIX) Q4 2023 Earnings Call Transcript March 5, 2024 Orthofix Medical Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.14. OFIX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon, and welcome to Orthofix […]

New Debt & Financing Risk for Orthofix International – What’s the Latest?

2024-03-07
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Orthofix price target raised by $3 at Roth MKM, here's why

2024-03-07
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.